Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Market Cap	425.51B +41.4%
Revenue (ttm)	163.02B +4.5%
Net Income	19.16B -11.9%
EPS	268.22 -9.1%
Shares Out	70.40M
PE Ratio	22.53
Forward PE	26.73
Dividend	45.00 (0.74%)
Ex-Dividend Date	n/a

Volume	101,300
Average Volume	282,900
Open	6,046.00
Previous Close	6,045.00
Day's Range	6,044.00 - 6,050.00
52-Week Range	3,861.00 - 6,695.00
Beta	0.28
RSI	49.22
Earnings Date	Apr 13, 2026

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,799
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4530

Financial Performance

In fiscal year 2026, TYO:4530's revenue was 163.02 billion, an increase of 4.50% compared to the previous year's 156.01 billion. Earnings were 19.16 billion, a decrease of -11.94%.